Management Change/Compensation (Form 8-K)

On May 14, 2026, the Board of Directors (the "Board") of Provectus Biopharmaceuticals, Inc. (the "Company") approved the conversion of accrued but unpaid directors' fees of current Board members owed through June 30, 2026 ("Accrued Fees") into the Company's Series D-1 Preferred Stock ("Preferred Stock") at a price per share equal to $2.862 and the issuance of this Preferred Stock to current Board members. The Preferred Stock is being issued to satisfy payment of outstanding cash fees owed to the Company's directors and is not being issued as a separate award under the Company's 2024 Equity Compensation Plan. The total amount of Accrued Fees through June 30, 2026 will be $542,500.00, which would convert into 189,554 shares of Preferred Stock, which would convert into 1,895,540 shares of Common Stock.

On April 12, 2017, the Board approved the accrual of directors' fees until such time as the Board authorized the payment of director compensation, as reported on the Company's Form 8-K filed on April 18, 2017.